Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 9/20 | 0.46 |
| ▸ | AXL | P30530 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697769 | 0.96 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL165288 | 0.96 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL22009936 | 0.92 | PDGFRA (0.56) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL29487188 | 0.91 | PDGFRA (0.59) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL174159 | 0.91 | PDGFRA (0.59) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL25281154 | 0.88 | PDGFRA (0.51) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL22960033 | 0.87 | KDR (0.50) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL29487138 | 0.87 | KDR (0.50) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL1133098 | 0.87 | AXL (0.59) | PDGFRAKDRMETAXLSRC | |
| SCHEMBL1133096 | 0.87 | AXL (0.59) | PDGFRAKDRMETAXLSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186318-B2 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) | 2015-11-17 | — | — | US | disclosed |
| US-9186318-B2 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) | 2015-11-17 | — | — | US | disclosed |
| US-8933230-B2 | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2015-01-13 | — | — | US | disclosed |
| US-8933230-B2 | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2015-01-13 | — | — | US | disclosed |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2014-08-07 | — | — | US | disclosed |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2014-08-07 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | HDAC5, HDAC1, HDAC7 | PDGFRA 2530/4885KDR 3893/4885FGFR2 1772/4885 |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | PDGFRA 229/4885KDR 148/4885FGFR2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.